Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02720445 · ClinicalTrials.gov registry record · Phase 2
Memory Improvement Through Nicotine Dosing (MIND) Study
A Phase 2 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 2
- Development phase
- 348
- Enrollment target
NCT02720445 is a Phase 2 study that has completed, run by University of Southern California. The registered enrollment target is 348 participants.
The verdict
NCT02720445, a Phase 2 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 348 participants
- Enrollment target
Study Summary
The purpose of the study is to see if daily transdermal nicotine is able to produce a significant cognitive, clinical and functional improvement in participants with MCI. Neuronal nicotinic receptors have long been known to play a critical role in memory function in preclinical studies, with nicotine improving attention, learning, and memory function. The study will enroll 380 participants for a 2 year period. Participants will be randomized (50:50) to either the transdermal nicotine, beginning at 7mg/day, and increasing to 21mg/day, or placebo skin patch.
Interventions
- DRUG Placebo Patch
- DRUG Nicotine Transdermal Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 2017-01-13 |
| Est. Completion | 2025-09-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02720445
The ClinicalTrials.gov registry entry for NCT02720445 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 348 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Patch is the first listed.
NCT02720445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02720445 about?
NCT02720445 is a clinical study titled "Memory Improvement Through Nicotine Dosing (MIND) Study". The purpose of the study is to see if daily transdermal nicotine is able to produce a significant cognitive, clinical and functional improvement in participants with MCI. Neuronal nicotinic receptors have long been known to play a critical role in memory function in preclinical studies, with nicotin...
What is the current status of trial NCT02720445?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 348 participants. The study started on 2017-01-13. Estimated completion is 2025-09-16.
What interventions are being tested in trial NCT02720445?
The interventions under investigation include: Placebo Patch (DRUG), Nicotine Transdermal Patch (DRUG).
Who is sponsoring clinical trial NCT02720445?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.